Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
Rhea-AI Summary
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company developing small molecule precision medicines for CNS disorders, has announced its participation in two major healthcare conferences in November 2024. The company will engage in fireside chats at the Stifel Healthcare Conference in New York City on November 18 at 1:15pm ET, and the Jefferies London Healthcare Conference on November 20 at 4:00pm GMT/11am ET. Live and archived webcasts will be available on the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RAPP declined 4.06%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will participate in fireside chats at two upcoming investor conferences as follows:
- The Stifel Healthcare Conference in New York City
Monday, November 18, 2024, at 1:15pm ET
- The Jefferies London Healthcare Conference
Wednesday, November 20, 2024, at 4:00pm GMT/11am ET
Interested parties may access the live and archived webcasts under the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformational precision neuromedicines for patients suffering from central nervous system (CNS) disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead clinical program, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently advancing RAP-219 in clinical trials in focal epilepsy, peripheral neuropathic pain, and bipolar disorder. Additional preclinical and late-stage discovery stage programs are also underway, targeting CNS disorders including chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
Source: https://www.rapportrx.com/
FAQ
When is Rapport Therapeutics (RAPP) presenting at the Stifel Healthcare Conference in 2024?
What time is Rapport Therapeutics (RAPP) presenting at the Jefferies London Healthcare Conference?
Where can investors watch Rapport Therapeutics' (RAPP) conference presentations?
What type of medicines does Rapport Therapeutics (RAPP) develop?
